

Ad hoc announcement pursuant to Art. 53 LR

Basel, 23 April 2026

Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

- **Group sales** were +6% at constant exchange rates (CER)¹, -5% when reported in CHF and +9% in USD², in the first three months, driven by high demand for our innovative medicines and diagnostics.
- **Pharmaceuticals Division sales** were +7% at CER, -4% when reported in CHF and +10% in USD, due to continued high growth in sales of medicines for the treatment of severe diseases; Xolair (chronic hives, food allergies), Phesgo (breast cancer), Hemlibra (haemophilia A), Vabysmo (severe eye diseases) and Ocrevus (multiple sclerosis) were the top growth drivers.
- **Diagnostics Division sales** were +3% at CER, -7% when reported in CHF and +7% in USD, as demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China.
- **Highlights:**
 - Positive data for: **fenebrutinib** for multiple sclerosis (phase III), **Gazyva/Gazyvaro** for an autoimmune condition affecting kidney function (phase III); and **petrelintide** for obesity (phase II)
 - CE mark for new **Elecsys NfL blood test** to detect neuroinflammation in multiple sclerosis, representing a breakthrough in disease management
 - Launch of the **cobas MPX-E assay**, a new 4-in-1 test to screen blood donors for HIV and hepatitis viruses
 - Launch of the **AI factory** to accelerate the development of new therapeutics and diagnostics solutions
 - Entry into a definitive **agreement to acquire SAGA Diagnostics**: SAGA's proprietary cancer therapy response monitoring platform will strengthen Roche's industry leading portfolio of oncology diagnostics and medicines
 - Inauguration of the new research home for the **Institute of Human Biology** to enable scientists to pioneer human model systems for research
- **Outlook for 2026 confirmed**

Roche CEO Thomas Schinecker: “We delivered a strong start to the year, achieving 6% Group sales growth at constant exchange rates.

Our pipeline continued to advance in areas where patients face significant unmet need, including multiple sclerosis, obesity and a severe autoimmune disease that can lead to kidney failure. We also received EU approval for a new test to detect neuroinflammation in multiple sclerosis, marking a meaningful step forward in disease management.

Our diversified portfolio across both divisions, together with continued pipeline progress, positions us well for sustained future growth in a dynamic geopolitical environment. We confirm our full-year outlook.”

Outlook for 2026

Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs.

Sales	CHF millions		As % of sales		% change		
	2026	2025	2026	2025	At CER	In CHF	In USD
January–March							
Group	14,722	15,440	100.0	100.0	+6	-5	+9
Pharmaceuticals Division	11,469	11,949	77.9	77.4	+7	-4	+10
United States	5,693	6,224	38.7	40.3	+5	-9	
Europe	2,234	2,320	15.2	15.0	-1	-4	
Japan	649	671	4.4	4.3	+14	-3	
International	2,893	2,734	19.6	17.8	+16	+6	
Diagnostics Division	3,253	3,491	22.1	22.6	+3	-7	+7

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others

Group sales

In the first three months of 2026, Roche **sales** were +6% at CER, -5% when reported in CHF, to CHF 14.7 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates.

Sales in the **Pharmaceuticals Division** were +7% at CER, -4% when reported in CHF, to CHF 11.5 billion, with medicines for severe diseases continuing their strong growth.

The top five growth drivers – Xolair, Phesgo, Hemlibra, Vabysmo and Ocrevus – achieved total sales of CHF 5.3 billion, an increase of 14% at CER, or 2% in CHF, compared to the first three months of 2025.

Sales of products with expired patents (Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra) decreased by a combined CHF 0.1 billion at CER, or CHF 0.2 billion in CHF.

In the **United States**, sales were +5% at CER, -9% when reported in CHF, due to continued growth of Xolair and continuing uptake of Hemlibra, Polivy (blood cancer), Ocrevus and Vabysmo. This growth more than compensated for the lower sales of Perjeta (breast cancer) and Kadcyla (breast cancer).

Sales in **Europe** were -1% at CER, or -4% when reported in CHF, due to lower sales of Polivy, the impact of biosimilar competition on Actemra/RoActemra and Perjeta (breast cancer) due to conversion to Phesgo. This decrease was partially offset by the demand for Ocrevus and Evrysdi (spinal muscular atrophy).

In **Japan**, sales were +14% at CER, -3% when reported in CHF, mainly due to product supply to third parties, as well as a strong uptake of Hemlibra, Vabysmo and Polivy. Sales growth was partially offset by the decline in sales of Tamiflu and the impact of biosimilar erosion on Avastin.

Sales in the **International** region were +16% at CER, or +6% when reported in CHF, led by Phesgo, Vabysmo, Polivy, Alecensa (lung cancer) and Ocrevus and partially offset by lower sales of influenza medicines Xofluza and Tamiflu. In China, sales were +14% at CER, or +5% when reported in CHF, as the uptake of Phesgo, Polivy and Vabysmo gained momentum following their inclusion in the government drug reimbursement list. The continued roll-out of Alecensa was the other growth driver. The increase was partially offset by lower sales of Xofluza and Perjeta.

The **Diagnostics Division's** sales were +3% at CER, -7% when reported in CHF, to CHF 3.3 billion as growth in demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China.

Sales in the **Europe, Middle East and Africa (EMEA)** region were +3% at CER, -2% when reported in CHF, driven by higher sales of clinical chemistry and immunodiagnostic products. In **North America**, sales were +6% at CER, -7% when reported in CHF, with growth across core, pathology and molecular lab areas. Sales in **Asia-Pacific** were -5% at CER, or -15% when reported in CHF, due to the healthcare pricing reforms in China. In **Latin America**, sales growth was +10% at CER, or 0% when reported in CHF.

Pharmaceuticals: key developments

Compound	Milestone
Regulatory	
Gazyva/Gazyvaro Lupus	<p>FDA accepts application for Gazyva/Gazyvaro for the treatment of the most common form of lupus</p> <ul style="list-style-type: none"> The filing was accepted based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE). If approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy to directly target B cells in SLE, potentially becoming the new standard of care for this condition. SLE is a potentially life-threatening autoimmune disease affecting more than three million people worldwide – achieving better disease control can reduce flares and may prevent irreversible organ damage.
Giredestrant Breast cancer	<p>FDA accepts New Drug Application for giredestrant in ESR1-mutated, ER-positive advanced breast cancer</p> <ul style="list-style-type: none"> Filing was accepted based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard-of-care endocrine therapy plus everolimus. Strength of evERA data demonstrates the potential for giredestrant combination to help address resistance to standard-of-care therapies, and that it could be the first and only oral SERD combination approved in the post-CDK4/6 inhibitor setting. The FDA has set a Prescription Drug User Fee Act date of 18 December 2026.
Phase III, pivotal and other key read-outs	
Enspryng MOGAD	<p>Enspryng reduces risk of relapses by 68%, demonstrating potential to become first treatment for MOGAD</p> <ul style="list-style-type: none"> The phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD is a rare autoimmune disease of the central nervous system characterised by unpredictable attacks of the optic nerves, spinal cord or brain that are often severe and debilitating. The data will be submitted to the regulatory authorities.

<p>Giredestrant Breast cancer</p>	<p>Roche provides update on phase III persevERA study in ER-positive advanced breast cancer</p> <ul style="list-style-type: none"> • The persevERA breast cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed. • Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment. • The FDA recently accepted the New Drug Application based on evERA data; phase III lidERA data has been submitted to the FDA.
<p>Petrelintide Obesity</p>	<p>Roche announces positive phase II results for petrelintide, an amylin analogue developed for people living with overweight and obesity</p> <ul style="list-style-type: none"> • Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7% with placebo (p-value <0.001) while demonstrating placebo-like tolerability. • At the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events. • The data support further development of petrelintide in chronic weight management as monotherapy and its tolerability profile also confirms its value as a combination partner.
<p>Fenebrutinib Multiple sclerosis</p>	<p>Fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive multiple sclerosis (MS) in third positive phase III study (FENhance 1)</p> <ul style="list-style-type: none"> • FENhance 1 met its primary endpoint, showing that investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), which is consistent with FENhance 2 results showing 59% reduction. • FENhance 1 is the final study read-out of the fenebrutinib pivotal clinical development programme in MS, following positive results for FENhance 2 in RMS and for FENtrepid in primary progressive multiple sclerosis (PPMS). • Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology.
<p>Gazyva/Gazyvaro Membranous nephropathy</p>	<p>Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in treatment of this autoimmune disease</p> <ul style="list-style-type: none"> • MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years. • Up to 30% of people with membranous nephropathy progress to kidney failure over 10 years despite current treatment approaches; achieving complete remission can help delay or prevent this. • Gazyva/Gazyvaro could become the first approved treatment for primary membranous nephropathy, having already achieved positive results in lupus nephritis, systemic lupus erythematosus and idiopathic nephrotic syndrome.

<p>Fenebrutinib Multiple sclerosis</p>	<p>Fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)</p> <ul style="list-style-type: none"> • Late-breaking phase III FENtrepid results presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2026 show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in reducing disability progression in PPMS. • Fenebrutinib numerically reduced the risk of disability progression by 12% compared to Ocrevus as early as 24 weeks; additional analysis showed potential benefit in upper limb function. • Fenebrutinib has the potential to become a first-in-class therapy in multiple sclerosis, as an oral, brain-penetrant BTK inhibitor for PPMS and relapsing multiple sclerosis (RMS)
<p>Other</p>	
<p>Institute of Human Biology</p>	<p>Roche inaugurates new research home for the Institute of Human Biology (IHB), pioneering human model systems to accelerate drug discovery and development</p> <ul style="list-style-type: none"> • The new building is part of a CHF 1.4 billion site investment, reinforcing Roche’s commitment to Switzerland and the Basel life sciences cluster. • The IHB enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients. • Federal Councillor Elisabeth Baume-Schneider, Head of the Federal Department of Home Affairs (FDHA), attended the official opening ceremony.
<p>AI factory</p>	<p>Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions</p> <ul style="list-style-type: none"> • With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totalling more than 3,500 GPUs. • The new computational infrastructure supports Roche’s vision of building an AI-accelerated healthcare organisation. • NVIDIA AI factories help accelerate discoveries, enable more efficient clinical trials and unlock data insights at scale, ultimately advancing innovation and improved healthcare outcomes.
<p>Annual General Meeting</p>	<p>Roche Annual General Meeting 2026</p> <ul style="list-style-type: none"> • Shareholders approved all proposals of the Board of Directors. • Severin Schwan was re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed. • Shareholders approved an increase of the dividend to CHF 9.80 per share; this is the 39th consecutive dividend increase. • Shareholders approved the exchange of non-voting equity securities (<i>Genussscheine</i>) for participation certificates.

Gazyva/Gazyvaro Lupus	<p>New England Journal of Medicine publishes phase III ALLEGORY data showing Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus</p> <ul style="list-style-type: none"> Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms. Gazyva/Gazyvaro has the potential to become a new standard of care for people living with systemic lupus erythematosus (SLE). If approved, Gazyva/Gazyvaro would be the first type II anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity.
Change in Enlarged Corporate Executive Committee	<p>Change to the Roche Enlarged Corporate Executive Committee</p> <ul style="list-style-type: none"> Roche announced the appointment of Mark Dawson, MD, PhD, as the new Head of Roche Pharma Research and Early Development (pRED), effective 1 May 2026. Based in Basel, he will also become a member of the Enlarged Corporate Executive Committee. Mark Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research. A leading expert in cancer biology, his work on chromatin regulation and epigenetics has been instrumental in defining the molecular mechanisms that drive cancer initiation and progression.

Pharmaceuticals sales

Sales	CHF millions		As % of sales		% change	
	2026	2025	2026	2025	At CER	In CHF
Pharmaceuticals Division	11,469	11,949	100.0	100.0	+7	-4
United States	5,693	6,224	49.6	52.1	+5	-9
Europe	2,234	2,320	19.5	19.4	-1	-4
Japan	649	671	5.7	5.6	+14	-3
International	2,893	2,734	25.2	22.9	+16	+6

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others

Top 20 best-selling pharmaceuticals (% change at CER ¹)	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus Multiple sclerosis	1,692	+6	1,117	+3	363	+9	-	-	212	+24
Hemlibra Haemophilia A	1,190	+13	613	+15	252	+5	81	+18	244	+14
Vabysmo Eye diseases (nAMD, DME, RVO)	1,024	+13	652	+4	190	0	37	+39	145	+126
Tecentriq Cancer immunotherapy	811	+4	378	+6	202	-6	69	0	162	+14
Xolair ³ Chronic hives, food allergies	708	+26	708	+26	-	-	-	-	-	-
Phesgo Breast cancer	686	+27	159	+2	206	+7	42	+23	279	+78
Perjeta ³ Breast cancer	672	-11	263	-12	119	-15	12	-19	278	-9
Actemra/RoActemra ³ RA, COVID-19	534	-4	248	-3	124	-16	66	+9	96	+5
Evrysdi Spinal muscular atrophy	464	+19	160	+15	159	+13	18	+4	127	+40
Kadcyla ³ Breast cancer	439	-4	156	-11	123	-6	19	+6	141	+5
Polivy Blood cancer	407	+26	171	+26	63	-32	46	+24	127	+120
Alecensa Lung cancer	401	+12	105	-7	63	-5	43	+4	190	+39
MabThera/Rituxan ³ Blood cancer, RA	292	+10	183	+16	31	-8	3	-6	75	+6
Activase/TNKase ³ Cardiac diseases	255	-2	244	-2	-	-	-	-	11	-4
Gazyva/Gazyvaro ³ Blood cancer, lupus nephritis	247	+10	115	+1	57	-2	9	+28	66	+45
Herceptin ³ Breast and gastric cancer	234	-12	44	-16	69	-7	1	-24	120	-14
Avastin ³ Various cancer types	224	-9	59	-15	14	+3	21	-29	130	-1

CellCept³ Immunosuppressant	99	+10	4	-5	28	-14	9	-16	58	+37
Enspryng Acute inflammation of brain, spinal cord and optic nerves	96	+31	22	+20	11	+20	35	+13	28	+93
Columvi Blood cancer	95	+77	43	+35	21	+84	-	-	31	+204

DME: diabetic macular edema / nAMD: neovascular or 'wet' age-related macular degeneration / RVO: retinal vein occlusion / RA: rheumatoid arthritis

Diagnostics: key developments

Product	Milestone
Elecsys NfL blood test Multiple sclerosis	<p>Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis (MS)</p> <ul style="list-style-type: none"> • The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis. • This minimally invasive blood test enables greater patient access to monitoring of neuroinflammatory status versus current standard of care methods. • By providing deeper insight into underlying neuroinflammatory activity, the Elecsys NfL blood test has the potential to enable effective MS monitoring and earlier clinical intervention.
cobas MPX-E assay HIV and hepatitis viruses	<p>Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply</p> <ul style="list-style-type: none"> • The cobas MPX-E test provides four critical results (for HIV, HCV, HBV and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs. • The new test delivers faster turnaround times and allows labs to implement hepatitis E (HEV) screening without requiring additional instrumentation. • This assay is designed for use on the fully automated cobas x800 systems, enabling high-throughput screening with up to 8 hours of walk-away time.

Diagnostics sales

Sales	CHF millions		As % of sales		% change	
	2026	2025	2026	2025	At CER	In CHF
January–March						
Diagnostics Division	3,253	3,491	100.0	100.0	+3	-7
Customer areas						
Core Lab	1,798	1,904	55.3	54.5	+4	-6
Molecular Lab	571	634	17.5	18.2	0	-10
Near Patient Care	465	536	14.3	15.4	-5	-13
Pathology Lab	419	417	12.9	11.9	+12	0
Regions						
Europe, Middle East, Africa	1,206	1,236	37.1	35.4	+3	-2
North America	1,073	1,154	33.0	33.1	+6	-7
Asia-Pacific	725	853	22.3	24.4	-5	-15
Latin America	249	248	7.6	7.1	+10	0

First Quarter Sales 2026 Webinar

There will be a live webinar for investors and analysts today, Thursday, 23 April at 2:00 pm CEST. To access the webinar, please click [here](#).

Additional Information

[First Quarter 2026 Sales Presentation](#)

[First Quarter 2026 Sales Presentation with appendix](#)

[Pharmaceuticals: key product launches in 2026](#)

[Diagnostics: key product launches in 2026](#)

About Roche

Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References

[1] CER (Constant Exchange Rates). The percentage changes at constant exchange rates are calculated using simulations by reconsolidating both the 2026 and 2025 results at constant exchange rates (the average rates for the year ended 31 December 2025). For the definition of CER, see page 178 of the Roche Finance Report 2025.

[2] USD (US dollars). The percentage changes for selected sales figures at US dollars are calculated by translating both the 2026 and 2025 sales figures at the respective average US dollar exchange rate for the period in question. This supplementary information is provided to assist readers when assessing comparability with other companies.

[3] Products launched before 2015.

Cautionary statement regarding forward-looking statements

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, such as: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Roche Investor Relations

Dr Bruno Eschli

Phone: +41 61 68-75284

e-mail: bruno.eschli@roche.com

Dr Sabine Borngräber

Phone: +41 61 68-88027

e-mail: sabine.borngraeber@roche.com

Dr Birgit Masjost

Phone: +41 61 68-84814

e-mail: birgit.masjost@roche.com

Investor Relations North America

Loren Kalm

Phone: +1 650 225 3217

e-mail: kalm.loren@gene.com

Appendix: Tables

1.	Sales January to March 2026 and 2025	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth Q1 2026 vs. Q1 2025.....	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth.....	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan.....	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10

1. Sales January to March 2026 and 2025

CHF millions	Three months ended 31 March		% change	
	2026	2025	At CER	In CHF
Pharmaceuticals Division	11,469	11,949	7	-4
United States	5,693	6,224	5	-9
Europe	2,234	2,320	-1	-4
Japan	649	671	14	-3
International	2,893	2,734	16	6
Diagnostics Division	3,253	3,491	3	-7
Roche Group	14,722	15,440	6	-5

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2026 and 2025

CHF millions	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025
Pharmaceuticals Div.	11,949	8	12,036	11	11,570	7	12,114	9	11,469	7
United States	6,224	6	6,446	13	6,128	5	6,557	9	5,693	5
Europe	2,320	5	2,246	5	2,252	5	2,346	7	2,234	-1
Japan	671	3	754	7	714	6	743	4	649	14
International	2,734	18	2,590	11	2,476	11	2,468	16	2,893	16
Diagnostics Division	3,491	0	3,468	0	3,348	2	3,540	6	3,253	3
Roche Group	15,440	6	15,504	8	14,918	6	15,654	8	14,722	6

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth Q1 2026 vs. Q1 2025

CHF millions	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	1,692	6	1,117	3	363	9	-	-	212	24
Hemlibra	1,190	13	613	15	252	5	81	18	244	14
Vabysmo	1,024	13	652	4	190	0	37	39	145	126
Tecentriq	811	4	378	6	202	-6	69	0	162	14
Xolair	708	26	708	26	-	-	-	-	-	-
Phesgo	686	27	159	2	206	7	42	23	279	78
Perjeta	672	-11	263	-12	119	-15	12	-19	278	-9
Actemra/RoActemra	534	-4	248	-3	124	-16	66	9	96	5
Evrysdi	464	19	160	15	159	13	18	4	127	40
Kadcyla	439	-4	156	-11	123	-6	19	6	141	5
Polivy	407	26	171	26	63	-32	46	24	127	120
Alecensa	401	12	105	-7	63	-5	43	4	190	39
MabThera/Rituxan	292	10	183	16	31	-8	3	-6	75	6
Activase/TNKase	255	-2	244	-2	-	-	-	-	11	-4
Gazyva	247	10	115	1	57	-2	9	28	66	45
Herceptin	234	-12	44	-16	69	-7	1	-24	120	-14
Avastin	224	-9	59	-15	14	3	21	-29	130	-1
CellCept	99	10	4	-5	28	-14	9	-16	58	37
Enspryng	96	31	22	20	11	20	35	13	28	93
Columvi	95	77	43	35	21	84	-	-	31	204
Elevidys	61	54	-	-	-	-	3	-	58	46
Itovebi	52	307	36	183	4	*	-	-	12	-
Rozlytrek	39	6	7	-43	6	18	1	-12	25	38

Lunsumio	37	101	24	95	4	-24	6	*	3	465
Luxturna	20	-33	20	-33	-	-	-	-	-	-
Xofluza	19	-86	7	-41	1	*	-	-	11	-91
PiaSky	14	88	-	-	3	246	11	72	-	-100
Cotellic	11	-5	5	-8	2	-13	-	-	4	4
Susvimo	4	138	4	138	-	-	-	-	-	-
Pharma other	642	-5	146	-28	119	4	117	31	260	-4
Pharma total sales	11,469	7	5,693	5	2,234	-1	649	14	2,893	16

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

* Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025
Ocrevus	1,778	6	1,728	10	1,684	6	1,820	16	1,692	6
Hemlibra	1,165	11	1,256	22	1,105	4	1,228	8	1,190	13
Vabysmo	1,018	18	1,049	19	996	4	1,039	7	1,024	13
Tecentriq	870	0	863	-1	883	4	950	8	811	4
Xolair	645	26	800	41	781	34	849	26	708	26
Phesgo	593	52	604	57	630	51	614	34	686	27
Perjeta	840	-10	773	-14	703	-14	652	-13	672	-11
Actemra/RoActemra	619	-1	660	8	614	-2	577	-10	534	-4
Evrysdi	420	18	449	-1	424	10	464	26	464	19
Kadcyla	506	5	531	12	494	7	494	6	439	-4
Polivy	358	42	372	51	371	30	369	31	407	26
Alecensa	397	11	405	6	388	8	372	1	401	12
MabThera/Rituxan	298	-16	332	1	303	3	318	-3	292	10
Activase/TNKase	297	-2	253	-7	283	1	274	-2	255	-2
Gazyva	249	15	241	12	238	13	258	15	247	10
Herceptin	292	-20	268	-23	257	-15	211	-29	234	-12
Avastin	274	-15	248	-19	241	-11	210	-21	224	-9
CellCept	98	4	98	1	96	18	93	-16	99	10
Enspryng	83	27	94	27	92	25	95	17	96	31
Columvi	60	138	63	58	79	71	86	64	95	77

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025
Ocrevus	1,247	3	1,215	8	1,151	1	1,261	17	1,117	3
Hemlibra	610	0	714	21	617	-1	724	6	613	15
Vabysmo	718	7	732	10	689	-4	718	-1	652	4
Tecentriq	411	-8	408	-4	403	2	418	4	378	6
Xolair	645	26	800	41	781	34	849	26	708	26
Phesgo	179	38	169	40	175	29	185	22	159	2
Perjeta	342	-3	335	4	291	-6	300	4	263	-12
Actemra/RoActemra	294	3	325	11	307	-6	280	-19	248	-3
Evrysdi	160	15	149	10	159	18	144	0	160	15
Kadcyla	201	5	195	9	181	2	191	10	156	-11
Polivy	156	30	171	34	170	18	191	32	171	26
Alecensa	130	21	146	19	144	15	145	4	105	-7
MabThera/Rituxan	181	-14	206	2	188	5	219	5	183	16
Activase/TNKase	285	-2	242	-5	270	1	259	-2	244	-2
Gazyva	131	27	122	14	123	14	143	20	115	1
Herceptin	60	-12	61	-8	54	-6	50	-14	44	-16
Avastin	80	-21	76	-18	69	-16	74	-14	59	-15
CellCept	5	-5	4	-26	5	3	7	10	4	-5
Enspryng	21	11	25	20	25	9	26	1	22	20
Columvi	37	124	41	88	47	90	53	70	43	35

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025
Ocrevus	344	11	362	14	354	12	391	14	363	9
Hemlibra	247	7	246	7	247	14	262	12	252	5
Vabysmo	197	42	181	25	178	9	185	13	190	0
Tecentriq	220	5	214	1	216	0	228	7	202	-6
Xolair	-	-	-	-	-	-	-	-	-	-
Phesgo	199	18	202	13	201	9	210	9	206	7
Perjeta	144	-16	138	-15	136	-14	134	-7	119	-15
Actemra/RoActemra	152	-19	156	-7	142	-1	138	-7	124	-16
Evrysdi	145	6	147	3	158	7	166	21	159	13
Kadcyla	135	-7	131	-5	130	-5	136	0	123	-6
Polivy	94	74	66	119	68	21	62	26	63	-32
Alecensa	68	-6	65	-7	64	-10	65	-3	63	-5
MabThera/Rituxan	35	-10	35	-6	34	13	36	-13	31	-8
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Gazyva	60	-3	61	4	62	1	62	5	57	-2
Herceptin	77	0	73	-2	73	2	68	-9	69	-7
Avastin	14	-33	12	-46	28	47	16	-22	14	3
CellCept	34	7	31	17	32	49	34	-19	28	-14
Enspryng	10	44	9	36	11	37	10	36	11	20
Columvi	12	92	13	70	18	51	19	65	21	84

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International

CHF millions	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024	Q4 2025	% change vs. Q4 2024	Q1 2026	% change vs. Q1 2025
Ocrevus	187	16	151	23	179	35	168	11	212	24
Hemlibra	226	72	195	60	149	9	140	18	244	14
Vabysmo	71	101	98	130	94	111	95	118	145	126
Tecentriq	158	21	148	7	176	17	217	25	162	14
Xolair	-	-	-	-	-	-	-	-	-	-
Phesgo	175	142	183	230	205	213	170	122	279	78
Perjeta	336	-9	281	-27	259	-21	203	-30	278	-9
Actemra/RoActemra	102	26	98	25	87	7	79	6	96	5
Evrysdi	95	56	127	-15	85	4	132	116	127	40
Kadcyla	149	21	181	33	160	28	144	9	141	5
Polivy	64	80	80	94	79	105	62	67	127	120
Alecensa	150	12	143	2	129	8	109	-3	190	39
MabThera/Rituxan	79	-23	87	2	77	-5	60	-22	75	6
Activase/TNKase	12	-9	11	-37	13	18	15	-4	11	-4
Gazyva	50	11	49	18	45	24	43	8	66	45
Herceptin	153	-29	132	-34	128	-25	92	-42	120	-14
Avastin	144	-3	120	-15	109	-13	86	-26	130	-1
CellCept	47	-4	51	-8	49	7	42	-18	58	37
Enspryng	15	171	19	40	14	60	15	32	28	93
Columvi	11	345	9	-16	14	48	14	45	31	204

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others